Connect Biopharma Holdings Ltd
connectbiopharma.comWhat Do They Do?
Develops an antibody candidate for people with asthma and COPD.
10-K for FY2025, filed Mar 31, 2026
Who Are Their Customers?
Simcere holds an exclusive license to develop, manufacture and commercialize rademikibart in Greater China; Connect retains rights in other markets.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
Narrower development portfolio
The older report described programs for atopic dermatitis, ulcerative colitis and chronic itch alongside asthma; the latest report says rademikibart is its only candidate in clinical development and focuses on acute asthma and COPD exacerbations.
20-F for FY2022, filed Apr 11, 2023 10-K for FY2025, filed Mar 31, 2026Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets. Our lead product…View ↗
CBP-307 is an investigational, oral small molecule modulator of S1P1, a regulator of T cell mobilization out of lymph nodes into the…View ↗
We are developing CBP-174, a peripherally acting, small molecule H3R antagonist, for oral administration to treat chronic itch associated…View ↗
Who Do They Compete With?
Competes with sanofi-aventis U.S., Regeneron Pharmaceuticals, AstraZeneca Pharmaceuticals, Teva Pharmaceutical Industries, Amgen, Genentech USA, Novartis Pharmaceuticals, and GlaxoSmithKline
10-K for FY2025, filed Mar 31, 2026If approved for chronic treatment of asthma or COPD, rademikibart would compete with currently available products including: DUPIXENT®…View ↗
Loading...
